Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,290,000.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the completion of the transaction, the chief executive officer now owns 257,054 shares in the company, valued at approximately $13,263,986.40. This trade represents a 8.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

David Alan Campbell also recently made the following trade(s):

• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00.

Janux Therapeutics Stock Performance

Shares of JANX traded down $1.61 during mid-day trading on Wednesday, reaching $46.39. 649,812 shares of the company were exchanged, compared to its average volume of 710,287. The business has a 50 day simple moving average of $50.02 and a two-hundred day simple moving average of $45.82. The stock has a market capitalization of $2.43 billion, a PE ratio of -39.65 and a beta of 3.52. Janux Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The business’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, analysts predict that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Janux Therapeutics

Several large investors have recently made changes to their positions in JANX. Summit Securities Group LLC bought a new stake in Janux Therapeutics during the 2nd quarter valued at $29,000. Amalgamated Bank raised its holdings in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the last quarter. Plato Investment Management Ltd bought a new position in Janux Therapeutics in the 2nd quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Janux Therapeutics in the second quarter valued at approximately $151,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. UBS Group initiated coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. Scotiabank lowered their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Wedbush reissued an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $67.70.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.